Previous close | 25.44 |
Open | 25.63 |
Bid | 24.91 x 100 |
Ask | 25.02 x 100 |
Day's range | 24.93 - 25.92 |
52-week range | 6.40 - 30.27 |
Volume | |
Avg. volume | 1,416,441 |
Market cap | 2.153B |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Clinical Trials Show Promise as Company Strengthens Financial Position
Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of the company on March 1, 2024, according to a recent SEC Filing.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]